PGD synthase Inhibitors

PGD synthase inhibitors encompass a class of compounds that can affect the enzyme's activity through various mechanisms. These inhibitors are not directly targeting the active site of the enzyme but act by modulating the availability of its substrates or by altering the synthesis and concentration of related signaling molecules. The majority of these compounds interfere with the cyclooxygenase (COX) enzymes, which are critical in the prostaglandin synthesis pathway. By inhibiting COX enzymes, these chemicals can decrease the levels of prostaglandins that serve as substrates for PGD synthase, thereby reducing its activity indirectly.

The chemical class of COX inhibitors includes both nonselective and selective compounds. Nonselective COX inhibitors, such as indomethacin, ibuprofen, naproxen, and diclofenac, can affect both COX-1 and COX-2 isoforms and are known to modulate the synthesis of various prostaglandins. Selective COX-2 inhibitors like celecoxib, rofecoxib, and etoricoxib are designed to specifically target the COX-2 isoenzyme, which is primarily involved in the inflammatory response and is a source of prostaglandins that are substrates for PGD synthase. These inhibitors can therefore indirectly reduce the enzymatic activity of PGD synthase by limiting the availability of its prostaglandin substrates. It is through these varied actions on the prostaglandin synthesis pathway that these compounds exert their influence on PGD synthase activity.